Testicular invading refractory multiple myeloma during bortezomib treatment successfully treated with lenalidomide: a case report

MeSH terms

• Angiogenesis Inhibitors / therapeutic use*
• Antineoplastic Agents / administration & dosage
• Antineoplastic Agents / therapeutic use
• Antineoplastic Combined Chemotherapy Protocols / administration & dosage
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
• Boronic Acids / therapeutic use
• Bortezomib
• Cyclophosphamide / administration & dosage
• Cyclophosphamide / therapeutic use
• Dexamethasone / administration & dosage
• Dexamethasone / therapeutic use
• Doxorubicin / administration & dosage
• Doxorubicin / therapeutic use
• Drug Resistance, Neoplasm
• Genital Neoplasms, Male / drug therapy
• Genital Neoplasms, Male / pathology
• Genital Neoplasms, Male / secondary
• Humans
• Lenalidomide
• Male
• Middle Aged
• Multiple Myeloma / drug therapy*
• Multiple Myeloma / prevention & control
• Multiple Myeloma / surgery
• Multiple Myeloma / therapy
• Neoplasm Invasiveness
• Orchiectomy
• Proteasome Inhibitors / administration & dosage
• Proteasome Inhibitors / therapeutic use
• Pyrazines / therapeutic use
• Secondary Prevention
• Spermatic Cord / drug effects
• Spermatic Cord / pathology
• Stem Cell Transplantation
• Testicular Neoplasms / drug therapy*
• Testicular Neoplasms / prevention & control
• Testicular Neoplasms / secondary
• Testicular Neoplasms / surgery
• Thalidomide / analogs & derivatives*
• Thalidomide / therapeutic use
• Vincristine / administration & dosage
• Vincristine / therapeutic use